MedPath
Found 274 clinical trials|View Analysis
Sort by:

Post-line Treatment with Teniposide for C-Myc-driven Extensive-stage Small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Thoracic Neoplasms
Lung Neoplasms
Lung Diseases
Interventions
Drug: Teniposide administration
First Posted Date
2025-01-06
Last Posted Date
2025-01-06
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
15
Registration Number
NCT06758700
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, China, Shanghai, Shanghai, China

Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer

Active, not recruiting
Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
First Posted Date
2024-12-27
Last Posted Date
2024-12-30
Lead Sponsor
Hunan Cancer Hospital
Target Recruit Count
600
Registration Number
NCT06748495
Locations
🇨🇳

Hunan Cancer Hospital, Changsha, Hunan, China

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Phase 1
Not yet recruiting
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Radiation: Low-dose radiotherapy
Drug: Tifcemalimab injection
Drug: Toripalimab
Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
First Posted Date
2024-12-13
Last Posted Date
2024-12-27
Lead Sponsor
Sichuan University
Target Recruit Count
12
Registration Number
NCT06732258

Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001)

Phase 3
Not yet recruiting
Conditions
Extensive-stage Small Cell Lung Cancer
Interventions
Radiation: High-dose Hyperfractionated Simultaneous Integrated Boost Radiotherapy
Drug: atezolizumab or durvalumab
First Posted Date
2024-12-05
Last Posted Date
2024-12-05
Lead Sponsor
Anhui Shi, MD
Target Recruit Count
182
Registration Number
NCT06719336

Safety and Effectiveness of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
BioNTech SE
Target Recruit Count
439
Registration Number
NCT06712355

Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin

Phase 2
Recruiting
Conditions
Lung Cancer, Small Cell
Interventions
Drug: Chemotherapy (Etoposide and Carboplatin)
Drug: Immunotherapy (Envafolimab)
Drug: Trilaciclib
First Posted Date
2024-11-21
Last Posted Date
2024-11-21
Lead Sponsor
Shanghai Chest Hospital
Target Recruit Count
52
Registration Number
NCT06698965
Locations
🇨🇳

Shanghai Chest Hospital, Shanghai, Shanghai, China

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Phase 2
Not yet recruiting
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
First Posted Date
2024-10-29
Last Posted Date
2024-10-29
Lead Sponsor
Gruppo Oncologico Italiano di Ricerca Clinica
Target Recruit Count
142
Registration Number
NCT06663098
Locations
🇮🇹

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy

🇮🇹

IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy

🇮🇹

IRCCS Azienda Ospedaliero_Universitaria di Bologna, Bologna, Italy

and more 22 locations

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Small Cell Lung Cancer Extensive Stage
Small Cell Lung Cancer Recurrent
Interventions
First Posted Date
2024-10-18
Last Posted Date
2024-10-18
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
100
Registration Number
NCT06648200
Locations
🇨🇳

Shanghai Pulmonary Hospital, Shanghai, China

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3
Not yet recruiting
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Biological: BMS-986489 (BMS-986012+Nivolumab)
Biological: Atezolizumab
Drug: Carboplatin
Drug: Etoposide
First Posted Date
2024-10-17
Last Posted Date
2024-12-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
530
Registration Number
NCT06646276
Locations
🇨🇳

Local Institution - 0335, Xi'an, Shaanxi, China

🇺🇸

Local Institution - 0245, Fort Myers, Florida, United States

🇺🇸

Local Institution - 0009, Orange City, Florida, United States

and more 150 locations

A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
SCLC, Extensive Stage
Interventions
Drug: Arm 1
Drug: second-line group
First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Target Recruit Count
70
Registration Number
NCT06620796
© Copyright 2025. All Rights Reserved by MedPath